Symbols / LGVN Stock $0.94 -3.73% Longeveron Inc.

Healthcare • Biotechnology • United States • NCM
LGVN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Stephen H. Willard Esq.
Exch · Country NCM · United States
Market Cap 27.52M
Enterprise Value 18.03M
Income -22.70M
Sales 1.20M
FCF (ttm) -11.17M
Book/sh 0.25
Cash/sh 0.20
Employees 38
Insider 10d —
IPO Feb 12, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.61
PEG —
P/S 22.96
P/B 3.81
P/C —
EV/EBITDA -0.82
EV/Sales 15.04
Quick Ratio 1.17
Current Ratio 1.33
Debt/Eq 14.52
LT Debt/Eq —
EPS (ttm) -1.29
EPS next Y -1.53
EPS Growth —
Revenue Growth -39.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-17
ROA -81.27%
ROE -164.75%
ROIC —
Gross Margin 66.97%
Oper. Margin -14.79%
Profit Margin 0.00%
Shs Outstand 27.80M
Shs Float 19.82M
Insider Own 5.68%
Instit Own 6.15%
Short Float 10.83%
Short Ratio 1.22
Short Interest 2.90M
52W High 1.83
vs 52W High -48.63%
52W Low 0.47
vs 52W Low 97.89%
Beta -0.19
Impl. Vol. —
Rel Volume 0.03
Avg Volume 5.59M
Volume 171.34K
Target (mean) $5.48
Tgt Median $4.00
Tgt Low $2.00
Tgt High $10.45
# Analysts 3
Recom None
Prev Close $0.98
Price $0.94
Change -3.73%
About

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.48
Mean price target
2. Current target
$0.94
Latest analyst target
3. DCF / Fair value
$-7.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.94
Low
$2.00
High
$10.45
Mean
$5.48

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-15 main Roth Capital Buy → Buy $3
2025-03-21 reit HC Wainwright & Co. Buy → Buy $10
2025-03-03 reit HC Wainwright & Co. Buy → Buy $10
2024-12-05 init Roth MKM — → Buy $10
2024-11-25 reit HC Wainwright & Co. Buy → Buy $10
2024-11-04 reit HC Wainwright & Co. Buy → Buy $10
2024-09-04 reit HC Wainwright & Co. Buy → Buy $10
2024-08-27 main Maxim Group Buy → Buy $6
2024-08-15 reit HC Wainwright & Co. Buy → Buy $10
2024-07-31 reit HC Wainwright & Co. Buy → Buy $10
2024-07-29 main HC Wainwright & Co. Buy → Buy $10
2024-05-17 reit HC Wainwright & Co. Buy → Buy $12
2024-04-29 main HC Wainwright & Co. Buy → Buy $12
2023-12-04 init HC Wainwright & Co. — → Buy $6
2023-05-16 reit EF Hutton Buy → Buy $13
2023-05-09 reit EF Hutton — → Buy $13
2023-03-27 reit EF Hutton — → Buy $13
2023-01-10 main EF Hutton — → Buy $13
2022-03-24 init Maxim Group — → Buy $14
2022-01-05 init EF Hutton — → Buy $20
News
RSS: Latest LGVN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-02 WILLARD STEPHEN H Chief Executive Officer — 400,000 $0.00 $0
2025-10-01 PALETTA GEORGE A JR. Director — 34,000 $0.00 $0
2025-09-04 POWELL JAMES NATHANIEL Chief Executive Officer — 50,000 $0.00 $0
2025-08-11 BALUCH KHOSO Director — 11,766 $0.70 $8,181
2025-08-11 LOCKLEAR LISA Chief Financial Officer — 11,766 $0.70 $8,181
2025-07-15 BALUCH KHOSO Director — 17,000 $0.00 $0
2025-07-15 SOFFER ROCK J Director — 17,000 $0.00 $0
2025-07-15 LEHR PAUL T General Counsel — 102,000 $0.00 $0
2025-07-15 UNGARO URSULA Director — 17,000 $0.00 $0
2025-07-15 HASHAD MOHAMED WA'EL AHMED Chief Executive Officer — 180,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.20
-49.87%
2.39
+237.38%
0.71
-41.98%
1.22
Operating Revenue
1.20
-49.87%
2.39
+237.38%
0.71
-41.98%
1.22
Cost Of Revenue
0.40
-22.05%
0.51
+4.10%
0.49
-32.69%
0.72
Reconciled Cost Of Revenue
0.40
-22.05%
0.51
+4.10%
0.49
-32.69%
0.72
Gross Profit
0.80
-57.38%
1.88
+752.49%
0.22
-55.53%
0.50
Operating Expense
24.09
+30.88%
18.41
-13.38%
21.25
+14.62%
18.54
Research And Development
12.04
+47.98%
8.14
-10.25%
9.07
-3.24%
9.37
Selling General And Administration
12.05
+17.33%
10.27
-15.72%
12.18
+32.87%
9.17
Selling And Marketing Expense
—
—
0.78
-25.50%
1.05
General And Administrative Expense
12.05
+17.33%
10.27
-15.72%
12.18
+50.07%
8.12
Other Gand A
12.05
+17.33%
10.27
-15.72%
12.18
+50.07%
8.12
Total Expenses
24.49
+29.46%
18.91
-12.99%
21.74
+12.84%
19.27
Operating Income
-23.29
-40.95%
-16.52
+21.43%
-21.03
-16.55%
-18.04
Total Operating Income As Reported
-23.29
-40.95%
-16.52
+21.43%
-21.03
-16.55%
-18.04
EBITDA
-22.06
-41.74%
-15.56
+22.50%
-20.08
-17.10%
-17.15
Normalized EBITDA
-21.96
-41.12%
-15.56
+22.39%
-20.05
-27.30%
-15.75
Reconciled Depreciation
1.23
+27.97%
0.96
+1.27%
0.95
+5.94%
0.89
EBIT
-23.29
-40.95%
-16.52
+21.43%
-21.03
-16.55%
-18.04
Total Unusual Items
-0.10
0.00
+100.00%
-0.03
+97.85%
-1.40
Total Unusual Items Excluding Goodwill
-0.10
0.00
+100.00%
-0.03
+97.85%
-1.40
Special Income Charges
-0.10
0.00
+100.00%
-0.03
+97.85%
-1.40
Other Special Charges
—
—
0.03
-97.85%
1.40
Net Income
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Pretax Income
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Net Non Operating Interest Income Expense
—
—
—
0.00
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
—
—
—
0.00
Interest Expense
—
—
—
0.00
Other Income Expense
0.58
+6.19%
0.55
+242.97%
-0.38
+51.52%
-0.79
Other Non Operating Income Expenses
0.68
+23.86%
0.55
+255.08%
-0.35
-158.42%
0.61
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Net Income From Continuing Operation Net Minority Interest
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Net Income From Continuing And Discontinued Operation
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Net Income Continuous Operations
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Normalized Income
-22.61
-41.53%
-15.97
+25.30%
-21.38
-22.63%
-17.44
Net Income Common Stockholders
-22.70
+7.79%
-24.62
-10.86%
-22.21
-17.92%
-18.84
Otherunder Preferred Stock Dividend
0.00
-100.00%
8.65
+983.96%
0.80
0.00
Diluted EPS
—
-2.62
+74.36%
-10.22
-13.56%
-9.00
Basic EPS
—
-2.62
+74.36%
-10.22
-13.56%
-9.00
Basic Average Shares
—
9.41
+333.00%
2.17
+3.65%
2.10
Diluted Average Shares
—
9.41
+333.00%
2.17
+3.65%
2.10
Diluted NI Availto Com Stockholders
-22.70
+7.79%
-24.62
-10.86%
-22.21
-17.92%
-18.84
Gain On Sale Of PPE
-0.10
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
10.26
-59.85%
25.56
+111.61%
12.08
-55.94%
27.41
Current Assets
5.45
-72.22%
19.62
+235.57%
5.85
-71.16%
20.28
Cash Cash Equivalents And Short Term Investments
4.66
-75.76%
19.23
+258.74%
5.36
-72.73%
19.66
Cash And Cash Equivalents
4.66
-75.76%
19.23
+288.60%
4.95
-52.88%
10.50
Other Short Term Investments
—
0.00
-100.00%
0.41
-95.50%
9.15
Receivables
0.10
+23.81%
0.08
-24.32%
0.11
-49.08%
0.22
Accounts Receivable
0.10
+316.00%
0.03
+66.67%
0.01
0.00
Other Receivables
—
0.06
-38.54%
0.10
-55.96%
0.22
Prepaid Assets
—
—
—
—
Current Deferred Assets
—
—
—
—
Other Current Assets
0.69
+122.73%
0.31
-18.09%
0.38
-6.93%
0.40
Total Non Current Assets
4.81
-18.94%
5.93
-4.75%
6.23
-12.66%
7.13
Net PPE
2.35
-29.48%
3.33
-11.17%
3.75
-16.29%
4.48
Gross PPE
8.17
-3.92%
8.51
+3.85%
8.19
+82.81%
4.48
Accumulated Depreciation
-5.82
-12.54%
-5.17
-16.53%
-4.44
-19.13%
-3.73
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.51
-41.84%
0.88
-27.76%
1.22
-20.25%
1.53
Machinery Furniture Equipment
3.25
+0.87%
3.22
+21.96%
2.64
+12.48%
2.35
Other Properties
—
0.88
-27.76%
1.22
-58.60%
2.95
Leases
4.41
+0.18%
4.40
+1.71%
4.33
+0.00%
4.33
Goodwill And Other Intangible Assets
2.29
-4.83%
2.40
+4.98%
2.29
-5.06%
2.41
Other Intangible Assets
2.29
-4.83%
2.40
+4.98%
2.29
-5.06%
2.41
Other Non Current Assets
0.18
-12.87%
0.20
+4.66%
0.19
-20.90%
0.24
Total Liabilities Net Minority Interest
4.59
+24.93%
3.67
-31.22%
5.34
-22.76%
6.91
Current Liabilities
4.09
+58.29%
2.58
-33.61%
3.89
-20.13%
4.87
Payables And Accrued Expenses
3.39
+76.76%
1.92
-31.22%
2.79
+16.20%
2.40
Payables
0.42
+327.27%
0.10
-84.48%
0.64
-63.56%
1.75
Accounts Payable
0.42
+327.27%
0.10
-84.48%
0.64
-63.56%
1.75
Current Accrued Expenses
2.97
+63.13%
1.82
-15.43%
2.15
+231.08%
0.65
Current Debt And Capital Lease Obligation
0.66
+5.14%
0.62
+5.06%
0.59
+5.14%
0.56
Current Capital Lease Obligation
0.66
+5.14%
0.62
+5.06%
0.59
+5.14%
0.56
Current Deferred Liabilities
0.04
+0.00%
0.04
-92.09%
0.51
+0.00%
0.51
Current Deferred Revenue
0.04
+0.00%
0.04
-92.09%
0.51
+0.00%
0.51
Other Current Liabilities
—
—
—
1.40
Total Non Current Liabilities Net Minority Interest
0.50
-54.18%
1.09
-24.79%
1.45
-29.05%
2.04
Long Term Debt And Capital Lease Obligation
0.17
-79.49%
0.82
-43.09%
1.45
-29.05%
2.04
Long Term Capital Lease Obligation
0.17
-79.49%
0.82
-43.09%
1.45
-29.05%
2.04
Other Non Current Liabilities
0.33
+24.53%
0.27
—
—
Stockholders Equity
5.67
-74.07%
21.89
+224.68%
6.74
-67.12%
20.50
Common Stock Equity
5.67
-74.07%
21.89
+224.68%
6.74
-67.12%
20.50
Capital Stock
0.02
+57.14%
0.01
+600.00%
0.00
-90.48%
0.02
Common Stock
0.02
+57.14%
0.01
+600.00%
0.00
-90.48%
0.02
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
22.93
+53.98%
14.89
+493.11%
2.51
+19.45%
2.10
Ordinary Shares Number
22.93
+53.98%
14.89
+493.11%
2.51
+19.45%
2.10
Additional Paid In Capital
137.96
+4.93%
131.48
+43.19%
91.82
+9.69%
83.71
Retained Earnings
-132.31
-20.71%
-109.61
-28.97%
-84.98
-35.38%
-62.77
Gains Losses Not Affecting Retained Earnings
—
—
0.00
+100.00%
-0.36
Other Equity Adjustments
—
—
—
-0.36
Total Equity Gross Minority Interest
5.67
-74.07%
21.89
+224.68%
6.74
-67.12%
20.50
Total Capitalization
5.67
-74.07%
21.89
+224.68%
6.74
-67.12%
20.50
Working Capital
1.36
-92.00%
17.04
+769.93%
1.96
-87.29%
15.41
Invested Capital
5.67
-74.07%
21.89
+224.68%
6.74
-67.12%
20.50
Total Debt
0.82
-43.05%
1.45
-29.10%
2.04
-21.65%
2.60
Capital Lease Obligations
0.82
-43.05%
1.45
-29.10%
2.04
-21.65%
2.60
Net Tangible Assets
3.39
-82.60%
19.49
+337.49%
4.45
-75.38%
18.09
Tangible Book Value
3.39
-82.60%
19.49
+337.49%
4.45
-75.38%
18.09
Current Notes Payable
—
—
—
—
Other Equity Interest
—
—
-0.10
+0.00%
-0.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.64
-34.45%
-13.87
+27.02%
-19.00
-36.03%
-13.97
Cash Flow From Continuing Operating Activities
-18.64
-34.45%
-13.87
+27.02%
-19.00
-36.03%
-13.97
Net Income From Continuing Operations
-22.70
-42.14%
-15.97
+25.41%
-21.41
-13.69%
-18.84
Depreciation Amortization Depletion
1.23
+27.97%
0.96
+1.27%
0.95
+5.94%
0.89
Depreciation And Amortization
1.23
+27.97%
0.96
+1.27%
0.95
+5.94%
0.89
Other Non Cash Items
—
—
-1.40
—
Stock Based Compensation
1.68
-27.96%
2.33
+14.57%
2.03
-6.23%
2.17
Asset Impairment Charge
—
0.00
-100.00%
0.29
0.00
Operating Gains Losses
0.10
—
—
1.40
Gain Loss On Investment Securities
—
—
—
1.40
Unrealized Gain Loss On Investment Securities
—
—
0.22
+29.41%
0.17
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
1.06
+185.33%
-1.24
-486.60%
0.32
+34.87%
0.24
Change In Receivables
-0.02
-174.07%
0.03
-74.77%
0.11
+165.24%
-0.16
Change In Prepaid Assets
-0.38
-655.88%
0.07
+142.86%
0.03
+122.95%
-0.12
Change In Payables And Accrued Expense
1.62
+285.78%
-0.87
-324.16%
0.39
-9.32%
0.43
Change In Accrued Expense
1.29
+490.06%
-0.33
-122.10%
1.50
+321.86%
-0.68
Change In Payable
0.33
+160.19%
-0.54
+51.48%
-1.11
-200.63%
1.11
Change In Account Payable
0.33
+160.19%
-0.54
+51.48%
-1.11
-200.63%
1.11
Change In Other Working Capital
-0.25
+64.72%
-0.72
-183.46%
-0.25
-330.91%
0.11
Change In Other Current Assets
0.03
+377.78%
-0.01
-117.65%
0.05
+440.00%
-0.01
Change In Other Current Liabilities
0.07
-75.09%
0.27
0.00
—
Investing Cash Flow
-0.59
+7.03%
-0.64
-107.82%
8.19
+1309.16%
-0.68
Cash Flow From Continuing Investing Activities
-0.59
+7.03%
-0.64
-107.82%
8.19
+1309.16%
-0.68
Net PPE Purchase And Sale
-0.24
+62.60%
-0.66
-117.61%
-0.30
+47.10%
-0.57
Purchase Of PPE
-0.24
+62.60%
-0.66
-117.61%
-0.30
+47.10%
-0.57
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.59
+40.02%
-0.99
-42.94%
-0.69
+18.93%
-0.86
Net Investment Purchase And Sale
0.00
-100.00%
0.35
-96.04%
8.88
+4860.89%
0.18
Sale Of Investment
0.00
-100.00%
0.35
-96.04%
8.88
—
Net Intangibles Purchase And Sale
-0.35
-3.86%
-0.34
+14.25%
-0.39
-36.93%
-0.29
Purchase Of Intangibles
-0.35
-3.86%
-0.34
+14.25%
-0.39
-36.93%
-0.29
Financing Cash Flow
4.67
-83.78%
28.79
+447.15%
5.26
+1133.79%
-0.51
Cash Flow From Continuing Financing Activities
4.67
-83.78%
28.79
+447.15%
5.26
+1133.79%
-0.51
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Short Term Debt Issuance
—
—
—
—
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
4.98
-61.29%
12.87
+141.03%
5.34
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
16.19
+16421.43%
0.10
+4800.00%
0.00
Net Other Financing Charges
-0.31
-16.92%
-0.27
-52.87%
-0.17
+65.95%
-0.51
Changes In Cash
-14.57
-202.02%
14.28
+357.17%
-5.55
+63.35%
-15.15
Beginning Cash Position
19.23
+288.60%
4.95
-52.88%
10.50
-59.07%
25.66
End Cash Position
4.66
-75.76%
19.23
+288.60%
4.95
-52.88%
10.50
Free Cash Flow
-19.24
-29.48%
-14.86
+24.55%
-19.70
-32.86%
-14.82
Common Stock Issuance
4.98
-61.29%
12.87
+141.03%
5.34
0.00
Interest Received CFO
0.00
-100.00%
0.06
-72.73%
0.22
—
Issuance Of Capital Stock
4.98
-61.29%
12.87
+141.03%
5.34
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category